![Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5938/TOC-Subject-Sample-2021-Health-Social-Care.jpg"})
ABSTRACT
Background: Opioid treatment programs (OTPs) permit patients to ingest daily methadone doses unsupervised and away from the clinic, a strategy that enhances treatment access and convenience but has the potential for mismanagement.
Objective: This retrospective review, conducted during the COVID-19 pandemic (5/2020–1/2022), evaluates the feasibility and acceptability of a commercially available electronic pillbox to safely administer methadone take-home tablets in a large community-based OTP (census >500 people).
Methods: Study participants (n = 24; 54% male, 46% female; M age = 63 years) had recently received more take-homes per visit to support national social distancing directives, and were instructed that they could maintain these privileges by agreeing to use the pillbox.
Results: Results demonstrate good demand feasibility as most participants (71%) agreed to use the pillbox. Good implementation feasibility was observed through safe and reliable delivery of most take-home tablets, with a staff support line to resolve technical issues. Acceptability was modest as six participants (25%) requested to return the pillbox despite losing some take-home privileges.
Conclusion: Results support continued use and study of the electronic pillbox to safely deliver and increase access to methadone take-home doses.
KEYWORDS:
Acknowledgments
We gratefully acknowledge Karen Reece, the Executive Director at Man Alive, and the Man Alive OTP staff, for their contributions to and overall support for this research. We also acknowledge Dr. Robert Brooner, the longtime director of ATS, for his thoughtful leadership and pioneering work with the electronic pillbox. Dr. Brooner passed away on February 26, 2023.
Disclosure statement
No potential conflict of interest was reported by the author(s).